Welcome to our dedicated page for Senestech news (Ticker: SNES), a resource for investors and traders seeking the latest updates and insights on Senestech stock.
SenesTech, Inc. (NASDAQ: SNES) generates news as a biotechnology company focused on fertility control for rodent management. Its announcements frequently highlight developments related to ContraPest®, Evolve Rat, and Evolve Mouse Birth Control, which are described as contraceptive products for rats and mice that fit into integrated pest management programs and reduce reliance on traditional rodenticides.
Investors and observers following SNES news will see regular updates on financial performance and growth in Evolve rodent birth control products. Quarterly press releases report record revenues, gross profit margins, and the share of revenue contributed by Evolve-branded products, as well as commentary on adjusted EBITDA and cash balances. These releases often discuss progress toward profitability and the impact of multi-channel distribution strategies.
Company news also covers operational and commercial milestones. Examples include the launch of Evolve Rat Birth Control on major e-commerce platforms and home improvement retailer websites, expanded retail coverage through partners and wholesalers, and municipal pilot deployments in U.S. cities. Additional updates describe international distribution relationships, such as the appointment of the Belize Raptor Center as an official distributor following regulatory approval in Belize.
Regulatory and capital markets activities appear in SenesTech’s news flow as well. The company issues press releases on warrant exercises, gross proceeds from financings, and participation in investor conferences. For readers tracking SNES, this news page offers a way to monitor how SenesTech reports on product adoption, distribution channels, municipal and community programs, and financing events over time.
SenesTech (NASDAQ: SNES) has announced a 1-for-10 reverse stock split effective July 24, 2024, at 4:01 p.m. Eastern Time. The company's common stock will continue trading on the Nasdaq Capital Market under the symbol 'SNES' and will begin trading on a split-adjusted basis on July 25, 2024. This decision follows stockholder approval at the annual meeting on July 11, 2024.
The reverse split will reduce SenesTech's issued common stock from 5,144,632 shares to approximately 514,464 shares. Stockholders' percentage interest in the company will remain unchanged, except for minor adjustments due to fractional shares. Proportional adjustments will be made to equity awards and warrants.
SenesTech (Nasdaq: SNES), a leader in fertility control for managing animal pest populations, announced the deployment of its Evolve™ fertility control solution in the U.S. Virgin Islands. This initiative, part of an international effort to control invasive species in environmentally sensitive regions, is administered by the Wild Ecology Group. Evolve™ will be used across over 60 islands and has been identified as a long-term, sustainable solution to invasive species proliferation. The initial multi-pallet order is already en route to the Virgin Islands, with regular orders scheduled. Evolve™ effectively addresses rodent overpopulation by reducing fertility rather than using poisons. The product is easy to deploy and suitable for various environments.
SenesTech has announced its participation in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024. CEO Joel Fruendt and CFO Tom Chesterman will present a webcast at 11:45am ET and host one-on-one meetings with investors. The webcast can be accessed via the conference home page or directly through a provided link, with a replay available post-event. Investors can schedule one-on-one meetings by contacting Lytham Partners or registering on the event's website.
SenesTech has launched its Evolve™ fertility control solution for rats on Amazon. Evolve, a minimum risk soft bait, aims to address rodent overpopulation by reducing fertility rather than using poisons. Previously available only to professionals, Evolve is now accessible to everyday consumers, aiming to revolutionize pest control. The product contains an active ingredient proven to reduce rodent fertility in independent studies. Currently, the U.S. rodent pest management market is valued over $1 billion annually, with significant growth in e-commerce sales. Increasing regulatory restrictions on traditional poisons further highlight the potential for Evolve's market expansion.
SenesTech, Inc. announced record quarterly revenues of $415,000 in Q1 2024, a 78% increase compared to Q1 2023. Their product Evolve™ is the biggest-selling product, contributing over 50% of revenue. The company secured distribution agreements, expanded its geographic reach, and introduced new products like Evolve Mouse. The financial results showed a net loss of $1.8 million, with an Adjusted EBITDA loss of $1.7 million. Cash at the end of March 2024 was $3.6 million. The management is optimistic about the commercial and development milestones achieved in 2024, including the launch of a dedicated Amazon store and expansion of the addressable market with Evolve Mouse.
SenesTech, Inc. (NASDAQ: SNES) will report financial results for its first quarter of 2024 on May 9, 2024, following the market close. A conference call is scheduled for the same day at 5:00 pm ET to discuss the results.
SenesTech, Inc. has launched Evolve™ Mouse, a revolutionary soft bait to control mouse populations, designated as a 'minimum risk' product by the U.S. Environmental Protection Agency. The product offers an effective and convenient solution for consumers and professionals, aiming to address the growing rodent pest management market.
Summary not available.
Summary not available.
Summary not available.